Pharmaceutical Spray Particle Size Testing: Methods, Standards, and Applications

Pharmaceutical spray particle size testing is a critical quality attribute for orally inhaled and nasal drug products, because droplet and particle size distribution directly determines where the active ingredient deposits in the respiratory tract. Accurate measurement of parameters such as Dv50, MMAD, and fine particle fraction supports formulation development, regulatory submission, and routine batch release. This article explains the scope, sample types, analytical methods, and applicable standards for pharmaceutical spray particle size evaluation performed by accredited third-party laboratories.

Technical Overview

Pharmaceutical spray particle size testing measures the droplet or particle size distribution of drug products delivered as sprays, aerosols, mists, or powders. For inhalation and nasal preparations, size is the single most influential factor governing therapeutic performance: droplets larger than approximately 10 µm tend to deposit in the oropharynx, particles between 1 µm and 5 µm reach the deep lung regions, and particles below about 1 µm may be exhaled without depositing at all.

Because of this strong size–deposition relationship, regulatory authorities and pharmacopoeial monographs treat particle size distribution as a critical quality attribute for these dosage forms. Comprehensive characterization typically combines complementary techniques: laser diffraction for rapid geometric droplet sizing of the emitted plume, cascade impaction for aerodynamic size and regional lung deposition prediction, and image-based or spectroscopic methods for API-specific and morphological analysis. Test programs are usually designed within a quality-by-design framework and executed by accredited third-party laboratories using validated instrumentation and standardized operating procedures.

• Geometric droplet size distribution of the emitted spray (laser diffraction)
• Aerodynamic particle size distribution (cascade impaction)
• API-specific and morphological particle characterization (imaging and spectroscopy)

Testing Samples

Metered-Dose Inhalers (MDIs)

Suspension and solution MDIs packaged in pressurized canisters with metering valves are tested for both the droplet size of the propellant-driven plume and, in suspension products, the primary particle size of the micronized active ingredient. Testing is performed at controlled actuation conditions, defined spray distances, and specified lifecycle points, including priming and tail-off phases.

Dry Powder Inhalers (DPIs)

DPI products, including capsule-based, blister-based, and reservoir devices, are tested for the aerodynamic size of the aerosolized powder cloud, the dispersion efficiency of the formulation, and the tendency of micronized drug and carrier particles such as lactose to form agglomerates at defined airflow rates.

Nasal Sprays and Nasal Aerosols

Aqueous pump-driven nasal sprays and suspension nasal products are tested for droplet size distribution, spray pattern, plume geometry, and spray velocity. Excessively fine droplets carry a risk of unintentional lung deposition, so the proportion of droplets below defined thresholds is closely monitored.

Liquid Spray Preparations

Throat sprays, oral mucosal sprays, dermal and topical sprays, disinfectant sprays, and fixed-combination pump products are characterized to demonstrate consistent plume behavior, uniform delivered dose, and droplet size profiles appropriate to the intended site of action.

Nebulizer Products and Bulk Solutions

Nebulizer solutions and suspensions are tested in combination with representative nebulizer devices to determine the respirable fraction of the generated aerosol mist and the droplet size delivered under simulated breathing conditions.

Raw Materials and Intermediates

Micronized active pharmaceutical ingredients, excipient powders, emulsions, and pre-fill intermediates are tested for primary particle size and aggregation state to support incoming material control and process development.

Testing Items

Typical test items and reported parameters for pharmaceutical spray particle size evaluation include:

• Droplet size distribution parameters: Dv10, Dv50, Dv90, span, and volume percentage below defined size cut-offs
• Mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of the aerosolized dose
• Fine particle fraction and fine particle dose, typically defined as the mass below 5 µm aerodynamic diameter
• Extra-fine fraction, typically the mass below 1 µm or 2 µm aerodynamic diameter
• Emitted dose, delivered dose uniformity, and dose uniformity through the life of the device
• Spray pattern and plume geometry (plume width, ovality, spray angle) at defined distances from the actuator
• Priming requirements, re-priming behavior, and tail-off characterization
• Primary API particle size in suspensions, before and after actuation
• Agglomerate content, particle shape descriptors, and API-versus-excipient particle differentiation

Testing Methods

Laser Diffraction

Laser diffraction is the primary technique for geometric droplet sizing of sprays and is performed in accordance with ISO 13320 and its national adoption GB/T 19077. The spray is actuated through an inhalation or spray cell positioned in the laser beam, and the scattered light pattern is converted into a volume-based size distribution using Mie theory. Time-resolved measurements capture the evolution of the plume during a single actuation, and measurements at multiple distances from the nozzle reflect evaporation and coalescence behavior under realistic breathing conditions.

Cascade Impaction

Cascade impaction remains the reference method for aerodynamic particle size distribution of inhaled products. Multi-stage impactors, such as the Next Generation Impactor and stacked Andersen-type impactors, are operated at pharmacopoeial flow rates with a breathing simulator where appropriate. Drug mass collected on each stage is quantified by validated analytical methods such as HPLC, and the resulting stage deposition profile is used to calculate MMAD, GSD, fine particle dose, and regional deposition estimates.

Dynamic Image Analysis

Dynamic image analysis of individual droplets and particles is conducted in line with ISO 13322. High-speed optical capture of the spray or suspended particles provides number-based size distributions as well as shape information, which is valuable for identifying elongated particles, agglomerates, and such as foreign particulates in suspensions.

Time-of-Flight Aerodynamic Sizing

Aerodynamic particle size analyzers based on time-of-flight or accelerated nozzle separation measure the aerodynamic diameter of individual airborne particles in real time, providing a rapid complement to cascade impaction during early development screening.

Microscopy and Morphology-Directed Chemical Imaging

Optical microscopy, electron microscopy, and Raman-assisted image analysis are used to determine primary particle size and morphology and to distinguish active ingredient particles from excipient particles in combination and suspension products, in line with ASTM E799 principles for drop size data handling.

Applications

Pharmaceutical spray particle size testing services are applied across the product lifecycle:

• Formulation and device development for MDIs, DPIs, nasal sprays, and nebulized products
• Selection and optimization of actuators, valves, pumps, and spray orifices
• Comparative studies and equivalence demonstration for locally acting generic products
• Stability studies assessing size drift, agglomeration, and dose delivery changes over shelf life
• Batches release testing and routine quality control against registered specifications
• Regulatory submission support, including CMC data packages and risk assessments
• Investigation of out-of-specification results, device defects, and manufacturing changes

FAQ

What particle size is required for pulmonary drug delivery?

An aerodynamic diameter between approximately 1 µm and 5 µm is generally accepted as optimal for deposition in the conducting airways and alveolar region. Larger particles are lost in the mouth and throat, while particles much smaller than 1 µm are largely exhaled.

What is the difference between droplet size and aerodynamic particle size?

Droplet size measured by laser diffraction is a geometric, volume-based measurement of the liquid droplets in the plume, whereas aerodynamic particle size measured by cascade impaction reflects aerodynamic behavior, incorporating density and shape, and is the parameter most directly related to respiratory deposition.

Which standards govern pharmaceutical spray particle size testing?

Laser diffraction is covered by ISO 13320 and GB/T 19077, dynamic image analysis by ISO 13322-2, and droplet size data criteria and processing by ASTM E799. Cascade impaction methods follow established pharmacopoeial and regulatory guidance for inhalation and nasal preparations.

How many actuations are required for a typical test?

The number of actuations depends on the technique and the product: laser diffraction may require several primed actuations per replicate, while cascade impaction studies typically collect and pool multiple actuations to reach quantifiable drug mass on each stage. Testing plans are customized to product sensitivity and study objectives.

Can the test distinguish API particles from excipient droplets?

Yes. By combining laser diffraction or imaging with chemical-specific analysis such as HPLC assay of impinger stages or morphology-directed Raman spectroscopy, laboratories can separately quantify the active ingredient distribution and the overall droplet distribution.

How should samples be submitted for testing?

Samples should be shipped under their registered storage conditions, with device priming status documented, sufficient units for replicate testing, and accompanying formulation information including refractive index data where available, to ensure accurate and reproducible measurements.